HOME >> MEDICINE >> NEWS
First large-scale clinical study establishes the efficacy of the new oral anticoagulant H 376/95

at high risk of venous thrombosis (formation of a blood clot in a vein) which may result in pulmonary embolism leading to death. A common approach to prevention of venous thromboembolism is the use of anticoagulant prophylaxis e.g. injectable low molecular weight heparin or oral warfarin. Warfarin requires careful and regular coagulation monitoring i.e. taking blood samples. Warfarin has limitations because of a slow onset of effect over several days. Also, bleeding complications and drug interactions are common. There is, therefore, a need for an effective and well-tolerated oral alternative to warfarin. The data from the METHRO II study indicate that H 376/95 shows considerable promise as a replacement for low molecular weight heparin and warfarin in the prophylaxis of venous thromboembolism in orthopaedic surgery."

The METHRO II study was a double-blind, dose-finding study and a comparator agent was used. The primary purpose of the study was to determine the dose-response relationship with regard to efficacy for the oral direct thrombin inhibitor, H 376/95, preceded by subcutaneous administration of melagatran. The METHRO II study was also designed to compare the efficacy of the H 376/95 regimen with conventional prophylaxis using the injectable low molecular weight heparin agent, dalteparin.

Patients were randomised to one of four melagatran/H 376/95 regimens or dalteparin for 8-11 days. The regimens were: 1mg, 1.5mg, 2.25mg or 3mg melagatran subcutaneously twice daily followed by 8mg, 12mg, 18mg or 24mg oral H 376/95 twice daily respectively or dalteparin 5000 IU once daily subcutaneously. A diagnostic procedure, phlebography, was carried out on the final day of treatment. Patient follow-up was 4-6 weeks post-operatively. Two-thirds of the patients underwent hip replacement and one-third knee replacement surgery. The age range was 18-85 years.

There was a clear relationship between the dose regimen of H 376/95 and the occurrence of
'"/>

Contact: Jonathan Wilson/Rebecca Hunt
jonathan.wilson@ketchumcomms.co.uk
44-207-465-7698
Ketchum
4-May-2000


Page: 1 2 3

Related medicine news :

1. First head-to-head study to compare lidoderm patch and Celebrex in treating pain
2. First UK cases of previously rare disease reported in gay men
3. First mouse model for multiple system atrophy points to new treatment targets for brain diseases
4. Mayo Clinic researchers create obedient virus; First step to use measles virus against cancer
5. First US kidney cancer vaccine trial underway at Columbia
6. First new treatment for alcoholism in ten years, now available Campral(R) (acamprosate calcium)
7. First blood test to diagnose paralyzing, blinding disease
8. First US SARS vaccine trial opens at NIH
9. First-ever safety study of medical cannabis use in Canada launched
10. First solid evidence that the study of music promotes intellectual development
11. First medical test on CD gets good results

Post Your Comments:
(Date:9/3/2015)... ... 2015 , ... TransPack Toon gives users a set of 90 cartoon transitions ... transitions in 30 different styles. Presets range from snow, underwater, forest, futuristic, city and ... Toon features 90 cartoon transitions from 30 unique styles. Editors can choose between ...
(Date:9/3/2015)... , ... September 03, 2015 , ... William Mattar Law ... Mattar, Esq. believes this does not stop at any certain demographic or segment of ... newly produced one-minute, thirty-, fifteen- and ten-second TV commercials. , The closed captioning will ...
(Date:9/3/2015)... Manchester, NH (PRWEB) , ... September 03, 2015 ... ... a new agreement with Amerinet Inc., a leading national healthcare solutions organization, to ... to Epic EMR. , Through this agreement, Amerinet members will receive negotiated pricing ...
(Date:9/3/2015)... ... September 03, 2015 , ... Mayo School of Graduate Medical ... Center for Hospice Care (CHC) for physician Hospice and Palliative Medicine Fellowship training ... of fulfilling their requirements for obtaining national Board Certification in Hospice and Palliative ...
(Date:9/3/2015)... ... September 03, 2015 , ... DriButts, a non-profit organization dedicated ... Product Development Group to manufacture a long-lasting reusable diaper for warm weather climates ... to bring 600 DriButts Diapers to rural areas of Haiti during a trip ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios Releases TransPack Toon, a New FCPX Transition 2Health News:Law Firm Focused on “Helping People” Continues to Expand on Vision 2Health News:E-Volve Health to Offer EMR Consulting Solutions to Amerinet Members 2Health News:Physicians from Mayo Clinic and Indiana University to Complete Hospice & Palliative Medicine Training at Center for Hospice Care 2Health News:DriButts Diapers Rely on Slingshot Help in Haiti 2Health News:DriButts Diapers Rely on Slingshot Help in Haiti 3
(Date:9/3/2015)... and ALISO VIEJO, Calif. , ... AGN ), a leading global pharmaceutical company, and ... company focused on developing ocular implants that reduce ... that they have entered into an agreement under ... transaction.  Under the terms of the agreement, Allergan ...
(Date:9/3/2015)... , Sept. 3, 2015 Research and ... the "Global Medical Devices Packaging Market - By ... Forecasts 2014 - 2020" report to their offering. ... market is driven directly by its end use industry, ... in the packaging of these devices so as to ...
(Date:9/3/2015)... 03, 2015 Research and ... "Investigation Report on China,s Entecavir Market, 2010-2019" ... people infected with hepatitis B virus (HBV) exceeds 100 ... 20-30 million suffering from chronic Hepatitis B. About 0.5 ... and liver cancer caused by chronic Hepatitis B, causing ...
Breaking Medicine Technology:Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 2Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 3Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 4Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 5Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 6Global Medical Devices Packaging Market 2015 - Market Trends and Forecasts to 2020 for the $21 Billion Industry 2Global Medical Devices Packaging Market 2015 - Market Trends and Forecasts to 2020 for the $21 Billion Industry 3Global Medical Devices Packaging Market 2015 - Market Trends and Forecasts to 2020 for the $21 Billion Industry 4Global Medical Devices Packaging Market 2015 - Market Trends and Forecasts to 2020 for the $21 Billion Industry 5Global Medical Devices Packaging Market 2015 - Market Trends and Forecasts to 2020 for the $21 Billion Industry 6Global Medical Devices Packaging Market 2015 - Market Trends and Forecasts to 2020 for the $21 Billion Industry 7Global Medical Devices Packaging Market 2015 - Market Trends and Forecasts to 2020 for the $21 Billion Industry 8China Entecavir Market Report 2010-2019 2
Cached News: